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1. Introduction 
Pharmacogenetics is the study of the relationship between genetic biomarkers and variation of individual drug 
response, metabolism, and transport. The application of clinical pharmacogenomics can provide a patient-
personalized approach to drug therapy by using genetic information to guide drug dosing and selection. Using 
patient pharmacogenetic information, healthcare providers can choose drugs that are more likely to be efficacious, 
avoid side effects, optimize patient-specific doses, and/or determine the need for closer monitoring. The US Food 
and Drug Administration lists over 140 therapeutic products with pharmacogenomic information in which specific 
action must be taken based on biomarker information [1] and various evidence-based, peer-reviewed guidelines 
on pharmacogenomic implementation guidelines [2, 3] exist to assist health providers in patient drug 
management. As the most accessible healthcare providers and medication experts, pharmacists are well-suited to 
direct and deliver pharmacogenomics-based patient care [4-7].  
 
Substantial scientific progress has been made in the understanding between genetic variation and variability of 
drug response and effect; however, pharmacogenomic testing has not been fully accepted or implemented in 
clinical practice. Potential barriers include cost-effectiveness and reimbursement, ethical concerns, and required 
educational and equipment infrastructure. Healthcare professionals, including pharmacists, report a lack of 
confidence in applying clinical pharmacogenomics despite the belief that it is important [4, 8]. Opportunities to 
improve patient care based on pharmacogenomic-guided recommendations are missed due to insufficient clinical 
training and knowledge of how to translate genetic test results into clinical action based on currently available 
evidence. While 92% of US pharmacy schools have incorporated pharmacogenomics into their curricula [9], only 
17% of practicing pharmacists reported their understanding of pharmacogenomics as 'excellent', 'very good', or 
'good' [10]. This knowledge gap is a significant barrier to widespread implementation of pharmacogenomic-based 
medicine and exposing student pharmacists early in the curriculum may further increase student comfort and 
foster a positive perspective towards pharmacogenomics [11-12]. Established core competencies outlined by the 
American Association of Colleges of Pharmacy (AACP) [13], Genetics/Genomics Competency Center (G2C2) [14] 
and the 2014 American Society of Health-System Pharmacists (ASHP) statement that pharmacists have a 
fundamental responsibility to ensure pharmacogenomics testing is performed when needed and that results are 
used to optimize medication therapy [15] may help strengthen the focus of pharmacogenomic education in 
PharmD program curriculums and advance the role of the profession.  
 
The purpose of this study was to evaluate the impact of an educational intervention including personal genotyping 
on student pharmacists’ attitudes and self-efficacy towards clinical pharmacogenomics. This study was a 
continuation of a previous study [16] and combines the results of both years. It was hypothesized that this 
innovative approach would lead to more real-life understanding of the benefits of personal genomics and clinical 
acceptance. 
 
2. Materials and Methods 
 
Subjects included second-year pharmacy students attending the UNC Eshelman School of Pharmacy during the Fall 
2014-Spring 2016 academic years. The student cohort included both the Chapel Hill and Asheville campuses who 
were enrolled in a 15-week course titled Pharmaceutical Care Lab (PCL), a requirement of the former “legacy” 
PharmD curriculum. Student participation in this study was voluntary and did not influence their coursework 
grade. This study was determined to be exempt from review by the UNC Institutional Review Board and was 
conducted in accordance to Good Clinical Practice, International Conference of Harmonization guidelines, and all 
applicable state and federal laws. 
 
The PCL consisted of once weekly 1-hour large group lecture with attendance from all second-year students and 4-
hour small group sessions consisting of 8-10 students per group. All students were led by clinical laboratory 
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instructors (e.g., PharmD residents, PharmD, post-graduate students, etc) in the large and small group sessions. 
Educational intervention materials consisted of 1) a PowerPoint presentation with background information about 
pharmacogenomics; 2) an educational video to help students understand basic methodologies employed in 
pharmacogenomics tests; 3) a demonstration to guide students through logistics of sample acquisition and pre-
testing consult using the 23andMe platform; 4) small group case reviews with hands-on training for managing drug 
therapies based on the pharmacogenomic results from a demo 23andMe test; and 5) exposure to real-world 
patient case scenarios through various counseling exercises. Further details describing the timing of the various 
components of the educational intervention are described in the Appendix. 
 
An anonymous electronic survey was administered during week 8 of the PCL course before the introductory 
pharmacogenomic presentation, and the same survey was conducted with additional questions upon completion 
of pharmacogenomic lecture series in week 15. The survey was adopted from prior published surveys on medical 
and graduate students’ attitudes towards genomics and personalized medicine [17-19] and modified to target 
student pharmacists. The survey gathered student demographics and assessed enrollment in previous genetics 
courses. Additionally, the survey questioned student pharmacists’ personal and professional attitudes and self-
efficacy in regards to clinical pharmacogenomics and personal genome testing. Survey questions prompted to 
respond to level of agreement with various statements using a ﬁve-point Likert scale (i.e., strongly agree, agree, 
neither agree nor disagree, disagree, and strongly disagree), yes/no, or yes/no/maybe answers.  Survey responses 
were linked using the same alphanumeric code for the pre- and post-intervention surveys to maintain student 
anonymity.  
 
The pharmacy students were offered voluntary personal genomic testing by the direct-to-consumer 23andMe test 
(Mountain View, CA) at a discounted price of $30.00 through funding from the UNC Center for Pharmacogenomics 
and Individualized Therapy (CPIT). Students were informed about the nature of their participation, including 
personal health information and potential risks before their participation. Willing participants could obtain the 
23andMe test on campus or online and ship his/her saliva samples directly to 23andMe with a prepaid shipping 
label. The results of the 23andMe genotype test were delivered within 4-8 weeks (prior to the completion of the 
PCL course) through a free online 23andMe account to be accessed solely by the student for personal use. 
23andMe provided participants with information limited to ancestry, carrier status, and genetic variability from the 
Illumina HumanOmniExpress-24 format chip consisting of 730,525 markers (San Diego, CA).  Students were 
instructed on how to use the 23andMe website and download raw data but were also provided with demo proﬁle 
information if they opted out of testing. Student pharmacists were referred to third party websites for detailed 
health information along with precautions and limitations of using various online resources. Student pharmacists 
also had the option of extracting personal pharmacogenomic data from the raw 23andMe genotype ﬁle using an 
Excel spreadsheet developed by our lab using gene haplotype translation tables from PharmGKB for CYP2C19, 
CYP2C9, CYP3A5, CYP2D6, DPYD, TPMT, G6PD, IFNL3, SLCO1B1, and VKORC1. The data could be interpreted by 
using hyperlinked Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines within the spreadsheet. 
None of the individual pharmacogenomic results from the 23andMe tests were accessed, collected, or used in any 
of the teaching materials or for any research purpose. 
 
Responses from the pre-intervention survey were collected for all student pharmacists to assess initial attitudes 
towards clinical pharmacogenomics. Data from students who completed both the pre- and post- intervention 
surveys was analyzed in a paired subset group and further delineated between those who underwent personal 
genotyping versus those who did not undergo personal genotyping. Students who responded to at least 70% of 
both the pre- and post- survey questions were included in the paired subset. Paired pre- and post-intervention 
survey responses were analyzed with McNemar’s test for binary comparisons and the Wilcoxon signed-rank test 
for Likert items. Responses between genotyped and nongenotyped students were analyzed with Fisher’s exact test 
for binary comparisons and the Mann-Whitney U-test for Likert items. Results were considered statistically 
signiﬁcant if p<0.05. 
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3. Results 
There were no statistically signiﬁcant demographical diﬀerences between students who completed the pre-
intervention survey and students in the paired subset group or between the genotyped and nongenotyped groups 
(Table 1). The median age of pharmacy students was 24 years. The majority of students reported their ethnicity as 
White or Caucasian (68%) and having taken a previous genetics course (62%). Prior to the initiation of this study, 
only one student in the paired subset had pharmacogenomic testing performed in a medical setting. Thirty-one 
percent of students who completed the pre-intervention survey (N=69/222) also completed the post-intervention 
survey, termed the paired subset. Fifty-five percent of students who completed both the pre-and post-surveys also 
obtained personal genotyping. 
 
Table 1. Study population demographics and previous experience with clinical genetics. 
The number (and percentage) of students with each corresponding characteristic is reported. 
 
Table 2 summarizes the differences between the paired subset overall, in addition to the differences between the 
genotyped and nongenotyped groups, after the educational intervention. In the post-survey, 36% of students in 
the paired subset reported that they would recommend personal genotyping for a patient compared to just 19% 
before the pharmacogenomic intervention (p=0.0032). Students were more confident (51% post-survey vs 29% 
pre-survey, p=0.0045) in applying pharmacogenomic information to manage patients’ drug therapy. Overall after 
the educational intervention, more students (51% pre-survey versus 90% post-survey) believed that personal 
genomics will likely play an important role in their future career (p=0.0072). There was a significant increase in the 
number of students who reported to be more familiar with pharmacogenomic resources for use in the clinical 
setting after the pharmacogenomic educational intervention regardless if they were genotyped (p<0.001). 
Students also became more confident in their ability to identify therapeutic areas in which pharmacogenomic 
testing is required or recommended. Students became more confident in their ability to interpret the results of 
pharmacogenomic testing from patients overall and within the genotyped groups, but not within the 
nongenotyped groups. More students reported that they could explain the rationale for pharmacogenomic testing 
in various therapeutic areas to patients than in the pre-survey (p=0.0074). Table A1 in the appendix lists additional 
findings between the paired subset and genotyped and nongenotyped groups after the educational intervention. 
 
Results for all students who completed the post-intervention survey regardless if they completed pre-intervention 
questionnaire are reported in Table A2 in the appendix. Students who were genotyped were more likely to believe 
that clinical pharmacogenomic cases should be incorporated into coursework (p=0.0384).  Additionally, more 
individuals who were genotyped agreed that information from a pharmacogenomic test may improve the way 
their medication treatment will be managed in the future (p=0.0094) and would recommend the use of 
 4 of 11 
 
pharmacogenomic testing to manage patient therapy prospectively (p=0.0259). There was a significant difference 
in the belief that the pharmacy profession should be more active in educating patients and other healthcare 
providers about pharmacogenomics between the genotyped and nongenotyped groups (p=0.0392). 
 
Table 2. Personal and professional reflections and attitudes towards pharmacogenomics and personal 
genotyping 
 
Survey Question 
Pre-
Intervention 
Survey 
Responders 
Paired Subset (N=69) Genotyped (N=38) Nongenotyped (N=31) 
Paired Subset 
Genotyped vs 
Nongenotyped 
(N=222) Pre Post pValue Pre Post pValue Pre Post pValue pValue 
The information from a 
pharmacogenomic test 
may improve the way 
my medication 
treatment is currently 
managed. 
187 (84%) 
19 
(28%) 
52 
(75%) 
0.0473 
34 
(89%) 
29 
(76%) 
0.0644 
26 
(84%) 
23 
(72%) 
0.513 0.3541 
The information from a 
pharmacogenomic test 
may improve the way 
my medication 
treatment will be 
managed in the future. 
204 (92%) 
66 
(95%) 
61 
(88%) 
0.1035 
37 
(97%) 
36 
(95%) 
0.8167 
29 
(93%) 
25 
(81%) 
0.109 0.0094 
Pharmacogenomics is 
useful in managing drug 
therapy. 
185 (83%) 
59 
(86%) 
56 
(81%) 
0.4721 
31 
(82%) 
32 
(84%) 
0.9528 
28 
(90%) 
24 
(77%) 
0.292 0.5922 
I am confident in my 
ability to understand 
the results of 
pharmacogenomic 
testing. 
113 (51%) 
28 
(41%) 
30 
(43%) 
0.4911 
15 
(39%) 
20 
(53%) 
0.1102 
13 
(42%) 
10 
(32%) 
0.478 0.1098 
I am familiar with 
pharmacogenomic 
resources (e.g., 
guidelines) for use in 
the clinical setting. 
55 (25%) 
12 
(17%) 
38 
(55%) 
<0.000
1 
8 
(21%) 
22 
(58%) 
<0.000
1 
4 
(13%) 
16 
(52%) 
0.0002 0.7042 
I would recommend the 
use of 
pharmacogenomic 
testing to manage 
therapy prospectively. 
139 (63%) 
44 
(64%) 
47 
(68%) 
0.2863 
27 
(71%) 
31 
(82%) 
0.8724 
17 
(55%) 
16 
(52%) 
0.21 0.0259 
I am confident in 
applying 
pharmacogenomic 
information to manage 
patients’ drug therapy. 
77 (35%) 
20 
(29%) 
35 
(51%) 
0.0045 
11 
(29%) 
22 
(58%) 
0.0029 
9 
(29%) 
13 
(42%) 
0.305 0.3406 
I know enough about 
genetics to understand 
personal genome test 
results. 
108 (49%) 
32 
(46%) 
41 
(59%) 
0.2151 
18 
(47%) 
25 
(66%) 
0.1405 
14 
(45%) 
16 
(52%) 
0.969 0.2631 
Personal genomics will 
likely play an important 
role in my future career. 
137 (62%) 
35 
(51%) 
55 
(90%) 
0.0072 
23 
(61%) 
32 
(84%) 
0.074 
12 
(39%) 
23 
(74%) 
0.095 0.084 
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Most pharmacists have 
enough knowledge to 
help individuals 
interpret results of 
personal genome tests. 
52 (23%) 
13 
(19%) 
21 
(30%) 
0.9936 
8 
(21%) 
11 
(29%) 
0.8978 
5 
(16%) 
10 
(32%) 
0.912 0.731 
Most people can 
accurately interpret 
their personal genome 
test results. 
13 (6%) 4 (6%) 
11 
(16%) 
0.7011 
3 
(17%) 
5 
(13%) 
0.5786 
1 
(3%) 
6 (19%) 0.274 0.1635 
I would recommend a 
personal genotyping 
test for a patient at this 
time. 
46 (21%) 
13 
(19%) 
25 
(36%) 
0.0032 
7 
(18%) 
14 
(37%) 
0.0923 
6 
(19%) 
11 
(35%) 
0.017 0.3482 
I can explain the 
rationale for 
pharmacogenomic 
testing in various 
therapeutic areas to 
patients. 
^ 
15 
(22%) 
54 
(78%) 
0.0074 
11 
(29%) 
31 
(82%) 
0.1172 
4 
(13%) 
23 
(64%) 
0.277 0.3293 
I can identify 
therapeutic areas in 
which 
pharmacogenomic 
testing is required. 
^ 
10 
(14%) 
45 
(65%) 
0.0138 
7 
(18%) 
27 
(71%) 
0.1445 
3 
(10%) 
18 
(58%) 
0.219 0.2786 
I can identify 
therapeutic areas in 
which 
pharmacogenomic 
testing is 
recommended. 
^ 
13 
(19%) 
52 
(75%) 
0.0268 
10 
(26%) 
32 
(84%) 
0.1328 
3 
(10%) 
20 
(65%) 
0.969 0.0263 
I can interpret the 
results of 
pharmacogenomic 
testing from patients. 
^ 
9 
(13%) 
33 
(48%) 
0.0305 
6 
(16%) 
20 
(53%) 
0.0469 
3 
(10%) 
13 
(42%) 
0.912 0.2651 
The pharmacy 
profession should be 
more active in 
educating patients and 
other healthcare 
providers about 
pharmacogenomics. 
^ 
22 
(32%) 
51 
(74%) 
0.8516 
13 
(34%) 
31 
(82%) 
1 
9 
(29%) 
20 
(65%) 
0.274 0.0392 
Items assessed on a five-point Likert scale are presented as the number and percentage of student pharmacists 
agreeing or strongly agreeing with the corresponding statement.  
* was not collected in the survey for the first year and the pre-survey for the second year 
-- was not collected in the survey for the first year 
^ was not collected in the pre-survey for the first year 
For students who elected to undergo personal genotyping (Table 3), 76% reported that their learning experience 
was enhanced by doing so and 71% claimed to have a better understanding of pharmacogenomics based on 
undergoing personal genotyping.  
 
Table 3. Reflections and attitudes towards personal genome testing for students who elected to undergo 
genotyping 
Survey Question 
Paired Subset Individuals who were Genotyped 
N=38 
My learning experience was enhanced by undergoing personal genotyping. 29 (76%) 
I have a better understanding of pharmacogenomics on the basis of undergoing personal 
genotyping 
27 (71%) 
Undergoing personal genotyping was an important part of my learning. 21 (55%) 
This course helped me understand what a patient’s experience might be like if they chose to 
undergo personal genome testing. 
32 (84%) 
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The cost for personal genome testing was reasonable 33 (87%) 
I would be willing to pay the full price (less than $100.00 plus shipping and handling) for 
personal genome testing. 
6 (15%) 
 I was pleased with my decision regarding personal genome testing. 34 (89%) 
I experienced anxiety when deciding whether to undergo personal genome testing. 6 (15%) 
I experienced anxiety when awaiting my personal genome testing results. 5 (13%) 
I experienced anxiety after receiving my personal genome testing results. 1 (2%) 
The opportunity to ask healthcare professional for help in interpreting the results is an 
important component to a personal genome testing offer. 
31 (81%) 
The personal genome testing experience was favorable. 15 (39%) 
The information received from personal genome testing was easy to understand. 10 (26%) 
The information received from personal genome testing was misused, mishandled, or 
misinterpreted. 
1 (2%) 
The information received from personal genome testing will be helpful when making clinical 
decisions in the future. 
9 (23%) 
 
4. Discussion 
As pharmacy schools are the leaders and innovators that drive pharmacy practice forward, educational 
interventions should have a positive and beneficial impact to shape student thoughts and impressions of 
pharmacogenomics that will ultimately be carried with them into clinical practice. Education in pharmacogenomics 
helps pharmacy students understand the clinical utility and application of pharmacogenomics-guided therapeutic 
drug selection and adjustment. Students demonstrated a signiﬁcant increase in their conﬁdence in applying clinical 
pharmacogenomic information and knowledge of clinical resources to manage patients’ drug therapy. Additionally, 
students were more likely to recommend personal genotyping for a patient.  
 
Limitations of this study include a relatively low response rate due to optional survey participation and a lack of a 
testing component to assess objective learning competencies. Despite an objective assessment of student 
learning, this study was beneficial to demonstrate that pharmacogenomic educational interventions can make a 
difference in student attitudes that could eventually lead to more acceptance of clinical pharmacogenomics in 
practice.  
 
As pharmacogenomic testing services become increasingly available to patients, either through healthcare 
providers or direct-to-consumer routes, there is more opportunity for pharmacists to provide pharmacogenomic 
counseling as an extension of medication-therapy-management (MTM) services. Pharmacists are ideally equipped 
to evaluate medication therapy challenges and implement solutions based on evidence-based precision medicine 
research. Healthcare professionals who are confident with their pharmacogenomic knowledge begins with 
adequate pharmacogenomic education. Effective pharmacogenomic educational interventions in PharmD 
curriculums can help pharmacy students better understand what a patient's personal genotyping experience might 
be like and empower them to implement these valuable clinical services in their practice as future pharmacists. 
 
President Barack Obama launched the Precision Medicine Initiative in his 2015 State of the Union address as an 
innovative approach to healthcare that takes into account individual differences in people’s genes, environments, 
and lifestyles [20]. Initially, the Precision Medicine Initiative focuses to identify genomic drivers in cancer for more 
effective approaches to treatment but is expected to further advance discoveries in genomic medicine in all 
therapeutic areas of patient care. With the increasing availability of testing services and declining testing costs [21-
23], along with evidence-based, peer-reviewed guidelines on pharmacogenomic implementation guidelines [2, 3], 
and practice models [24-27], the routine use of clinical pharmacogenomic testing is within reach. 
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Appendix  
During week 8 of the 1-hour large student group session of PCL, student pharmacists completed a pre-intervention 
survey before observing an introductory lecture on pharmacogenomics. In this same lecture, students received 
information regarding voluntary, anonymous personal genomic testing through 23andMe (Mountain View, CA). 
The large group lecture included the following student learning objectives: deﬁne pharmacogenomics, discuss the 
importance of pharmacogenomics in drug therapy, examine how pharmacogenomics is used to manage drug 
therapy, and provide examples of pharmacogenomic-guided algorithms.  
 
During week 11 in the small group sessions of PCL, pharmacogenomic patient cases using demo 23andMe data 
were discussed and relevant pharmacogenomic clinical resources were reviewed. A ﬁnal lecture was given in week 
15 of PCL to the large, complete student group with the following student learning objectives: discuss 23andMe 
results, demonstrate how to obtain pertinent pharmacogenomic information and utilize online resources, and 
review a clinical case focusing on the use of pharmacogenomics to manage drug therapy. Throughout the 
educational intervention, eight diﬀerent drug-gene pairs were described using clinical cases. After the wrap-up 
lecture in week 15, students were asked to complete the post-intervention survey. 
 
Table A1. Additional personal and professional reflections and attitudes towards pharmacogenomics and 
personal genotyping 
Survey Question 
Pre-
Intervention 
Survey 
Responders 
Paired Subset (N=69) Genotyped (N=38) Nongenotyped (N=31) 
Paired Subset 
Genotyped vs 
Nongenotyped 
(N=222) Pre Post pValue Pre Post pValue Pre Post pValue pValue 
I am comfortable with 
the use of my 
pharmacogenomic 
information to guide 
clinicians in selecting 
the appropriate 
medication for me. 
161 (73%) 
50 
(72%) 
51 
(74%) 
0.8625 
28 
(74%) 
30 
(79%) 
0.8439 
22 
(71%) 
21 
(68%) 
1 0.4504 
I am comfortable with 
the use of my 
pharmacogenomic 
information to guide 
clinicians in selecting 
the appropriate dose of 
my medication. 
159 (72%) 
50 
(72%) 
48 
(70%) 
0.3781 
29 
(76%) 
28 
(74%) 
0.3533 
21 
(68%) 
20 
(65%) 
0.79 0.5757 
I would want the drug 
or dosage of my 
medicine to be selected 
based on the results of 
pharmacogenomic 
testing. 
* 
37 
(54%) 
20 
(29%) 
0.8872 
12 
(32%) 
12 
(32%) 
0.8438 
8 
(26%) 
8 (25%) 1 0.1841 
I would want the drug 
or dosage of my 
medicine to be changed 
based on the results of 
pharmacogenomic 
testing. 
* 
20 
(29%) 
19 
(28%) 
0.393 
10 
(26%) 
12 
(32%) 
0.7949 
9 
(29%) 
7 (22%) 0.172 0.1027 
Pharmacogenomic 
information should be 
stored in the patient's 
medical record. 
169 (76%) 
56 
(86%) 
56 
(81%) 
0.4672 
30 
(79%) 
31 
(82%) 
0.9542 
26 
(84%) 
25 
(81%) 
0.285 0.3507 
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Pharmacogenomics will 
likely play an important 
role in my future career. 
165 (74%) 
53 
(77%) 
57 
(83%) 
0.657 
31 
(82%) 
34 
(89%) 
0.9896 
22 
(71%) 
23(74%) 0.689 0.438 
I understand the risks of 
using personal genome 
testing services. 
-- 
8 
(12%) 
13 
(19%) 
0.4034 
6 
(16%) 
8 
(21%) 
1 
2 
(6%) 
5 (16%) 0.277 0.9634 
I understand the 
benefits of using 
personal genome 
testing services. 
-- 
15 
(22%) 
23 
(33%) 
0.2056 
10 
(26%) 
13 
(34%) 
0.6172 
5 
(16%) 
10 
(32%) 
0.219 0.5685 
Most physicians have 
enough knowledge to 
help individuals 
interpret results of 
personal genome tests. 
48 (22%) 
10 
(14%) 
19 
(28%) 
0.7498 
5 
(13%) 
10 
(26%) 
0.8294 
5 
(16%) 
9 (29%) 0.877 0.5478 
Personal genome 
testing companies 
provide an accurate 
analysis and 
interpretation of 
genotype data. 
46 (21%) 
14 
(20%) 
22 
(32%) 
0.7314 
9 
(25%) 
12 
(32%) 
0.958 
5 
(16%) 
10 
(32%) 
0.804 0.6758 
Personal genome 
testing companies 
should be regulated by 
the federal government 
(i.e., the Food and Drug 
Administration). 
129 (58%) 
39 
(57%) 
41 
(59%) 
0.9315 
22 
(58%) 
23 
(61%) 
0.6575 
17 
(55%) 
18 
(58%) 
0.705 0.7559 
I can discuss the risks of 
pharmacogenomic 
testing with patients. 
-- 
6 
(9%) 
11 
(16%) 
0.328 
4 
(11%) 
9 
(24%) 
0.1582 
2 
(6%) 
2 (6%) 0.095 0.0584 
I can discuss the 
benefits of 
pharmacogenomic 
testing with patients. 
-- 
17 
(25%) 
25 
(36%) 
0.0783 
11 
(29%) 
14 
(37%) 
0.1875 
6 
(19%) 
11 
(35%) 
0.877 0.5711 
Items assessed on a five-point Likert scale are presented as the number and percentage of student pharmacists 
agreeing or strongly agreeing with the corresponding statement.  
* was not collected in the survey for for the first year and the pre-survey for the second year 
-- was not collected in the survey for the first year 
^ was not collected in the pre-survey for the first year 
Table A2. Post-intervention professional reflections and attitudes towards personal genotyping in genotyped 
versus nongenotyped groups 
Survey Question Genotyped (N=53) Nongenotyped (N=55) p-value 
The Pre-Pharmaceutical Care Lab lecture enhanced my learning of 
pharmacogenomics.  39 (74%) 36 (65%)  0.5035 
The cases in Pharmaceutical Care Lab enhanced my learning of 
pharmacogenomics. 35 (66%) 34 (62%)  0.6653 
The supplementary class materials for interpreting personal pharmacogenomic 
results are useful. 34 (64%) 27 (49%)  0.4720 
The supplementary class materials for additional personal genome testing 
results are useful. 35 (66%) 29 (55%)  0.3158 
More time should be spent on pharmacogenomics material in Pharmaceutical 
Care Lab. 17 (32%) 8 (15%) 0.9278 
More time should be spent on pharmacogenomics material in the curriculum. 20 (38%) 18 (33%) 0.4547 
A separate pharmacogenomics course should be required in the curriculum. 12 (23%) 9 (16%)  0.8097 
An elective pharmacogenomics course should be available in the curriculum.  48 (91%) 39 (71%)  0.1583 
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Pharmacogenomics should be covered early in the curriculum prior to 
therapeutic coursework. 24 (45%) 11 (20%)  0.4202 
Pharmacogenomics should be covered as needed in therapeutic coursework.  
48 (91%) 42 (76%)  0.0135 
Pharmacogenomics should be covered in practical clinical coursework.  41 (77%) 31 (56%)  0.6082 
Pharmacogenomics cases should be incorporated into coursework.  37 (70%) 26 (47%)  0.0384 
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